Last reviewed · How we verify
NCT04867564
Radiation-induced Cardiac Toxicity After Non-small Cell Lung Cancer Radiotherapy
trial testing Echocardiography in Non-small Cell Lung Cancer in 100 participants. Status unknown.
1 May 2024
Quick facts
| Lead sponsor | Military Institute od Medicine National Research Institute |
|---|---|
| Status | Status unknown |
| Study type | OBSERVATIONAL |
| Enrollment | 100 |
| Start date | 1 May 2021 |
| Primary completion | 1 May 2024 |
| Estimated completion | 1 May 2024 |
| Sites | 1 location across Poland |
Drugs / interventions tested
- Echocardiography
Conditions studied
- Non-small Cell Lung Cancer — all drugs for Non-small Cell Lung Cancer →
- Radiation Toxicity — all drugs for Radiation Toxicity →
- Cardiac Toxicity — all drugs for Cardiac Toxicity →
Sponsor
Military Institute od Medicine National Research Institute
Who can join
18 and older, any sex, with Non-small Cell Lung Cancer or Radiation Toxicity. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Despite the growing interest in investigating how the radiotherapy (RT) dose to anatomical substructures of the heart links to survival, the heart substructures at risk remain poorly defined. They are not delineated routinely as part of the RT planning process and there is no consensus on their dose constrains. With improving prognosis for non-small cell lung cancer (NSCLC) patients, the evidence relating irradiation of the heart to excess mortality has begun to accumulate. The study aims to evaluate subclinical cardiac dysfunction in consecutive NSCLC patients treated with definitive RT and to investigate the predictive value of the heart substructures dosimetric parameters for subclinical and overt cardiac toxicity as assessed using traditional and speckle tracking echocardiography (STE). The study will also investigate whether subclinical alterations detected by echocardiography with strain imaging may serve as a marker for future clinical dysfunctions.
Publications & conference data
2 peer-reviewed publications reference this trial (live from Europe PMC):
-
Association of Sinoatrial Node Radiation Dose With Atrial Fibrillation and Mortality in Patients With Lung Cancer.
Kim KH, Oh J, Yang G, Lee J, et al · · 2022 · cited 59× · PMID 36136325 · DOI 10.1001/jamaoncol.2022.4202 -
Radiation-induced cardiac substructure damage and dose constraints: a review.
Li X, Wu Y, Wang Q, Li B, et al · · 2025 · cited 3× · PMID 40474260 · DOI 10.1186/s13014-025-02668-x
Verify or expand the search:
- PubMed search for NCT04867564
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Echocardiography
Trials testing the same drug.
- NCT06863402 — Nemtabrutinib and Pembrolizumab for the Treatment of Richter Transformation, Diffuse Large B-cell Lymphoma Subtype · Phase 2 · recruiting
- NCT07372859 — Women's Heart: Impact of Ultra-endurance and Hormonal Profile on Cardiac and Systemic Inflammatory Parameters in Female · NA · not yet recruiting
- NCT06434064 — Tamoxifen and Pegylated Liposomal Doxorubicin for the Treatment of Patients With Metastatic or Inoperable, Locally Advan · Phase 2 · recruiting
- NCT06871410 — Genetically Engineered Cells (CD83 CAR T Cells) for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia · Phase 1 · recruiting
- NCT07375433 — Heart Failure With Preserved Ejection Fraction in Patients With Сhronic Obstructive Pulmonary Disease: Clinical Course a · recruiting
Other recruiting trials for Non-small Cell Lung Cancer
Currently open trials in the same condition.
- NCT07431827 — MK-3475A±Calderasib (MK-1084) in Completely Resected Stage IIA-IIIB (N2) KRAS G12Cm NSCLC (MK-1084-013) · Phase 3 · recruiting
- NCT05987956 — Pharmacogenomics IND EXEMPT SNP Clinical Trial - Alectinib and Single Nucleotide Polymorphisms · Phase 2, PHASE3 · active not recruiting
- NCT07195695 — Beamion LUNG-3: A Study to Test Whether Zongertinib Helps People With Surgically Removed, Non-small Cell Lung Cancer Wit · Phase 3 · recruiting
- NCT06686771 — Radiotherapy to Block Oligoprogression In Metastatic Non-Small-Cell Lung Cancer · Phase 3 · recruiting
- NCT06477055 — The Recurrence Gene Profiles of Adjuvant Osimertinib Therapy in Resected Non-Small-Cell Lung Cancer · recruiting
Other Military Institute od Medicine National Research Institute trials
Trials by the same sponsor.
- NCT07462000 — Aqueous Humor and Ocular Tissue Analysis in Glaucoma and Cataract · NA · recruiting
- NCT07395180 — Differentiation of Human Body Balance Disorders · NA · active not recruiting
- NCT06012552 — Randomized, Double-blind, Placebo-controlled Trial of the Efficacy and Safety of Tianeptine in the Treatment of Covid Fo · Phase 2 · recruiting
- NCT05716880 — Ketoanalogues for Muscle Mass Loss in Nephrotic Syndrome · Phase 3 · recruiting
- NCT05516160 — Perceptually Calibrated Scale of Optical Aberrations · NA · unknown
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04867564 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Military Institute od Medicine National Research Institute
- Last refreshed: 23 July 2021
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04867564.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing